• Why Attend?
  • Speakers
  • Contact Us

Why Attend?

As the pharma industry faces challenges with costs, it is essential to reduce the timeline for early-phase clinical trials, and the location can make a crucial difference.

This webinar will explore the regulatory environment for clinical trials in Europe and explain how the UK has a competitive advantage over the European Union.

When the UK left the EU in 2016, many were unsure how this would impact clinical trials. Yet ten years on, efficiencies have been unlocked by industry leaders such as Nucleus Network.

In this online event, industry experts will share key details on the regulatory differences between the UK and EU, opportunities to shorten early-phase trial timelines, and how this can lead to faster approvals so that more patients can benefit.

Why attend

  • A comparison of the UK and EU regulatory environments for early-phase trials
  • Why bring your early-phase trials to the UK
  • How Nucleus Network can support your early-phase drug development

Speakers

Select a speaker to learn more

Back
Dr. Sally Dowen
Vice President Operations UK – HMR | Nucleus Network London

Dr Sally Dowen is Vice President, Clinical Operations UK at Nucleus Network and a recognised leader in early phase clinical development with more than 20 years of experience spanning regulatory agencies, CRO leadership, and clinical trial delivery.

Prior to joining Nucleus Network, Sally served as Head of Clinical Trials at the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and as Director of Clinical Science and Regulatory Affairs at a leading UK early phase CRO, where she held overall responsibility for Clinical Project Management, Regulatory Affairs, and Medical Writing.

A specialist in early phase development, Sally has overseen more than 200 Phase I and II clinical trials across a broad range of therapeutic areas, including oncology, immunology, infectious diseases, CNS disorders, respiratory disease, diabetes, dermatology, and gastrointestinal conditions. Her expertise includes first-in-human studies, adaptive and multipart trial designs, SAD and MAD studies, food effect and drug-drug interaction studies, bioavailability and bioequivalence trials, ADME investigations, thorough QT studies, imaging trials, and studies involving special patient populations.

Known for combining deep scientific and regulatory expertise with practical operational leadership, Sally works closely with sponsors to navigate complexity, solve challenges, and optimise trial outcomes.

In addition to her industry leadership roles, Sally serves as Alternate Vice Chair of the London-Brent Research Ethics Committee, is a member of the UK Health Research Authority's Phase 1 Expert Advisory Group and the MHRA Phase 1 Stakeholder Group, and is a guest lecturer at King's College London. She holds a BA in Natural Sciences and a PhD in Molecular Oncology from the University of Cambridge, as well as a Certificate in Human Pharmacology from the Royal College of Physicians.

Next speaker
Back
Dr Graham Wood
Chief Scientific Officer, Nucleus Network

Dr Graham Wood is Chief Scientific Officer at Nucleus Network and brings over 26 years of clinical research experience to the role. He provides global scientific leadership, advising clients on clinical pharmacology study design and overseeing complex studies, with a particular focus on the Minneapolis clinic. He holds a PhD in Neurology and Neurosurgery from McGill University and has contributed to more than 350 first-in-human studies and over 2,000 trials in clinical pharmacology. His career includes senior executive roles in leading clinical research organizations and biotechnology companies, and his strategic leadership and operational focus continue to drive innovation across Nucleus Network’s global operations.

Next speaker

Enquiry